Over the last twelve months Bristol-Myers Squibb Company's share price has decreased from 61.24 to 60.58, changing by -1.08%. 1832 Asset Management L.P. raised its stake in shares of Bristol-Myers Squibb by 0.7% in the first quarter.
08/08/2016 - Bristol-Myers Squibb Company had its "hold" rating reiterated by analysts at Jefferies. The prior close of the stock price is recorded at $48.18. 9 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Bristol-Myers Squibb Company (BMY).
Bristol-Myers Squibb Co (NYSE:BMY) remained bullish with an increase +0.64% putting the price on the $60.97 per share in last trading session ended on 8/11/2016. Bearish revenue estimates established at 4.56 Billion while the bullish revenue forecast has been figured out at 4.92 Billion. Quantitative Investment Management LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $1,430,000.
The broker said it has now set a "Hold" rating on shares of Bristol-Myers Squibb Company with a price target of 70.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 23,200 shares of the business's stock in a transaction on Friday, July 8th. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. The stock was sold at an average price of $74.45, for a total value of $1,727,240.00.
Heavy trading for short periods will not mean much will not mean much, however, a trend of heavy trading volume on the buy side or on the sell side over a period of days or weeks sends a signal to market traders that institutions may be moving in or out of a stock, so institutional sponsorship is very important. Following the completion of the sale, the director now owns 380,099 shares in the company, valued at approximately $28,298,370.55. The disclosure for this sale can be found here. Finally, Chesley Taft & Associates LLC raised its stake in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Mizuho Trust & Banking Co. Chesley Taft & Associates LLC now owns 18,799 shares of the biopharmaceutical company's stock worth $1,201,000 after buying an additional 50 shares during the period. Professional analysts now have a consensus one-year price target of $70.70 on the shares. Bristol-Myers Squibb Co makes up approx 0.06% of Nordea Investment Management Ab's portfolio.
08/08/2016 - Bristol-Myers Squibb Company was downgraded to "neutral" by analysts at Credit Suisse. Bristol-Myers Squibb has an average rating of "Hold" and an average target price of $71.85.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. In terms of margins, Bristol-Myers Squibb Company has a gross margin of 75.70%, with its operating margin at 20.80%, and Bristol-Myers Squibb Company has a profit margin of 16.30%. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics.